-
1
-
-
0003964363
-
-
American Cancer Society, American Cancer Society, Atlanta, [accessed at 10.04.13]
-
American Cancer Society Cancer facts & figures 2012 2012, American Cancer Society, Atlanta, [accessed at 10.04.13]. http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-key-statistics.
-
(2012)
Cancer facts & figures 2012
-
-
-
2
-
-
80052714639
-
Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up
-
ESMO Guidelines Working Group
-
Cardoso F., Fallowfield L., Costa A., Castiglione M., Senkus E. Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011, 22(Suppl.6):vi25-vi30. ESMO Guidelines Working Group.
-
(2011)
Ann Oncol
, vol.22
, Issue.SUPPL.6
-
-
Cardoso, F.1
Fallowfield, L.2
Costa, A.3
Castiglione, M.4
Senkus, E.5
-
4
-
-
0021708673
-
Quantitation and intracellular localization of the 85K heat shock protein by using monoclonal and polyclonal antibodies
-
Lai B.T., Chin N.W., Stanek A.E., Keh W., Lanks K.W. Quantitation and intracellular localization of the 85K heat shock protein by using monoclonal and polyclonal antibodies. Mol Cell Biol 1984, 4:2802-2810.
-
(1984)
Mol Cell Biol
, vol.4
, pp. 2802-2810
-
-
Lai, B.T.1
Chin, N.W.2
Stanek, A.E.3
Keh, W.4
Lanks, K.W.5
-
5
-
-
84857039457
-
Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers
-
Jhaveri K., Taldone T., Modi S., Chiosis G. Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim Biophys Acta 2012, 1823:742-755.
-
(2012)
Biochim Biophys Acta
, vol.1823
, pp. 742-755
-
-
Jhaveri, K.1
Taldone, T.2
Modi, S.3
Chiosis, G.4
-
6
-
-
33846861747
-
Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors
-
Powers M.V., Workman P. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr Relat Cancer 2006, 13:S125-S135.
-
(2006)
Endocr Relat Cancer
, vol.13
-
-
Powers, M.V.1
Workman, P.2
-
7
-
-
84874267225
-
The therapeutic target Hsp90 and cancer hallmarks
-
Miyata Y., Nakamoto H., Neckers L. The therapeutic target Hsp90 and cancer hallmarks. Curr Pharm Des 2013, 19:347-365.
-
(2013)
Curr Pharm Des
, vol.19
, pp. 347-365
-
-
Miyata, Y.1
Nakamoto, H.2
Neckers, L.3
-
8
-
-
84863872604
-
Breast cancer and HSP90 inhibitors: is there a role beyond the HER2-positive subtype?
-
De Mattos-Arruda L., Cortes J. Breast cancer and HSP90 inhibitors: is there a role beyond the HER2-positive subtype?. Breast 2012, 21:604-607.
-
(2012)
Breast
, vol.21
, pp. 604-607
-
-
De Mattos-Arruda, L.1
Cortes, J.2
-
9
-
-
0141596939
-
Structure and functional relationships of Hsp90
-
Prodromou C., Pearl L.H. Structure and functional relationships of Hsp90. Curr Cancer Drug Targets 2003, 3:301-323.
-
(2003)
Curr Cancer Drug Targets
, vol.3
, pp. 301-323
-
-
Prodromou, C.1
Pearl, L.H.2
-
10
-
-
84872011968
-
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration
-
Liberati A., Altman D.G., Tetzlaff J., Mulrow C., Gøtzsche P.C., Ioannidis J.P., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. JClin Epidemiol 2009, 62:e1-34.
-
(2009)
JClin Epidemiol
, vol.62
-
-
Liberati, A.1
Altman, D.G.2
Tetzlaff, J.3
Mulrow, C.4
Gøtzsche, P.C.5
Ioannidis, J.P.6
-
11
-
-
84866375177
-
Aphase I dose-escalation trial of trastuzumab and alvespimycin hydrochloride (KOS-1022; 17 DMAG) in the treatment of advanced solid tumors
-
Jhaveri K., Miller K., Rosen L., Schneider B., Chap L., Hannah A., et al. Aphase I dose-escalation trial of trastuzumab and alvespimycin hydrochloride (KOS-1022; 17 DMAG) in the treatment of advanced solid tumors. Clin Cancer Res 2012, 18:5090-5098.
-
(2012)
Clin Cancer Res
, vol.18
, pp. 5090-5098
-
-
Jhaveri, K.1
Miller, K.2
Rosen, L.3
Schneider, B.4
Chap, L.5
Hannah, A.6
-
12
-
-
84856217356
-
Aphase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancer
-
Gartner E.M., Silverman P., Simon M., Flaherty L., Abrams J., Ivy P., et al. Aphase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancer. Breast Cancer Res Treat 2012, 131:933-937.
-
(2012)
Breast Cancer Res Treat
, vol.131
, pp. 933-937
-
-
Gartner, E.M.1
Silverman, P.2
Simon, M.3
Flaherty, L.4
Abrams, J.5
Ivy, P.6
-
13
-
-
79960985354
-
HSP90 inhibition is effective in breast cancer: a phase II trial oftanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab
-
Modi S., Stopeck A., Linden H., Solit D., Chandarlapaty S., Rosen N., et al. HSP90 inhibition is effective in breast cancer: a phase II trial oftanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin Cancer Res 2011, 17:5132-5139.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 5132-5139
-
-
Modi, S.1
Stopeck, A.2
Linden, H.3
Solit, D.4
Chandarlapaty, S.5
Rosen, N.6
-
14
-
-
36849055007
-
Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breastcancer: a phase I dose-escalation study
-
Modi S., Stopeck A.T., Gordon M.S., Mendelson D., Solit D.B., Bagatell R., et al. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breastcancer: a phase I dose-escalation study. JClin Oncol 2007, 25:5410-5417.
-
(2007)
JClin Oncol
, vol.25
, pp. 5410-5417
-
-
Modi, S.1
Stopeck, A.T.2
Gordon, M.S.3
Mendelson, D.4
Solit, D.B.5
Bagatell, R.6
-
15
-
-
84859794081
-
Aphase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors
-
Iyer G., Morris M.J., Rathkopf D., Slovin S.F., Steers M., Larson S.M., et al. Aphase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors. Cancer Chemother Pharmacol 2012, 69:1089-1097.
-
(2012)
Cancer Chemother Pharmacol
, vol.69
, pp. 1089-1097
-
-
Iyer, G.1
Morris, M.J.2
Rathkopf, D.3
Slovin, S.F.4
Steers, M.5
Larson, S.M.6
-
16
-
-
34250197902
-
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer
-
Solit D.B., Ivy S.P., Kopil C., Sikorski R., Morris M.J., Slovin S.F., et al. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res 2007, 13:1775-1782.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 1775-1782
-
-
Solit, D.B.1
Ivy, S.P.2
Kopil, C.3
Sikorski, R.4
Morris, M.J.5
Slovin, S.F.6
-
17
-
-
23044441106
-
Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies
-
Banerji U., O'Donnell A., Scurr M., Pacey S., Stapleton S., Asad Y., et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. JClin Oncol 2005, 23:4152-4161.
-
(2005)
JClin Oncol
, vol.23
, pp. 4152-4161
-
-
Banerji, U.1
O'Donnell, A.2
Scurr, M.3
Pacey, S.4
Stapleton, S.5
Asad, Y.6
-
18
-
-
20944444881
-
Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers
-
Ramanathan R.K., Trump D.L., Eiseman J.L., Belani C.P., Agarwala S.S., Zuhowski E.G., et al. Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Clin Cancer Res 2005, 11:3385-3391.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 3385-3391
-
-
Ramanathan, R.K.1
Trump, D.L.2
Eiseman, J.L.3
Belani, C.P.4
Agarwala, S.S.5
Zuhowski, E.G.6
-
19
-
-
79952734485
-
Aphase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors
-
Pacey S., Wilson R.H., Walton M., Eatock M.M., Hardcastle A., Zetterlund A., et al. Aphase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors. Clin Cancer Res 2011, 17:1561-1570.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 1561-1570
-
-
Pacey, S.1
Wilson, R.H.2
Walton, M.3
Eatock, M.M.4
Hardcastle, A.5
Zetterlund, A.6
-
20
-
-
77951907072
-
Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors
-
Ramanathan R.K., Egorin M.J., Erlichman C., Remick S.C., Ramalingam S.S., Naret C., et al. Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors. JClin Oncol 2010, 28:1520-1526.
-
(2010)
JClin Oncol
, vol.28
, pp. 1520-1526
-
-
Ramanathan, R.K.1
Egorin, M.J.2
Erlichman, C.3
Remick, S.C.4
Ramalingam, S.S.5
Naret, C.6
-
21
-
-
58149180924
-
Aphase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors
-
Tse A.N., Klimstra D.S., Gonen M., Shah M., Sheikh T., Sikorski R., et al. Aphase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors. Clin Cancer Res 2008, 14:6704-6711.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 6704-6711
-
-
Tse, A.N.1
Klimstra, D.S.2
Gonen, M.3
Shah, M.4
Sheikh, T.5
Sikorski, R.6
-
22
-
-
50349093362
-
Aphase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies
-
Ramalingam S.S., Egorin M.J., Ramanathan R.K., Remick S.C., Sikorski R.P., Lagattuta T.F., et al. Aphase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies. Clin Cancer Res 2008, 14:3456-3461.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 3456-3461
-
-
Ramalingam, S.S.1
Egorin, M.J.2
Ramanathan, R.K.3
Remick, S.C.4
Sikorski, R.P.5
Lagattuta, T.F.6
-
23
-
-
79955603500
-
Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors
-
Hubbard J., Erlichman C., Toft D.O., Qin R., Stensgard B.A., Felten S., et al. Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors. Invest New Drugs 2011, 29:473-480.
-
(2011)
Invest New Drugs
, vol.29
, pp. 473-480
-
-
Hubbard, J.1
Erlichman, C.2
Toft, D.O.3
Qin, R.4
Stensgard, B.A.5
Felten, S.6
-
24
-
-
84856032294
-
Efficacy and safety of retaspimycin hydrochloride (IPI-504) in combination with trastuzumab in patients (pts) with pretreated, locally advanced or metastatic HER2-positive breast cancer
-
Abstract 590
-
Modi S., Saura C., Henderson C.A., Lin N.U., Mahtani R.L., Goddard J., et al. Efficacy and safety of retaspimycin hydrochloride (IPI-504) in combination with trastuzumab in patients (pts) with pretreated, locally advanced or metastatic HER2-positive breast cancer. JClin Oncol 2011, 29. Abstract 590.
-
(2011)
JClin Oncol
, vol.29
-
-
Modi, S.1
Saura, C.2
Henderson, C.A.3
Lin, N.U.4
Mahtani, R.L.5
Goddard, J.6
-
25
-
-
51449115938
-
Aphase 1 dose-escalation study of the safety and pharmacokinetics (PK) of the oral Hsp90 inhibitor SNX-5422
-
Abstract 14613
-
Bryson J.C., Infante J.R., Ramanathan R.K., Jones S.F., Von Hoff D.D., Burris H.A. Aphase 1 dose-escalation study of the safety and pharmacokinetics (PK) of the oral Hsp90 inhibitor SNX-5422. JClin Oncol 2008, 26(Suppl.):636. Abstract 14613.
-
(2008)
JClin Oncol
, vol.26
, Issue.SUPPL.
, pp. 636
-
-
Bryson, J.C.1
Infante, J.R.2
Ramanathan, R.K.3
Jones, S.F.4
Von Hoff, D.D.5
Burris, H.A.6
-
26
-
-
84857036694
-
Use of biomarkers and imaging to evaluate the treatment effect of AUY922, an Hsp90 inhibitor, in patients with HER2+ or ER+ metastatic breast cancer
-
Schroder C., Pederson J.V., Chua S., Swanton C., Akimov M., Ide S., et al. Use of biomarkers and imaging to evaluate the treatment effect of AUY922, an Hsp90 inhibitor, in patients with HER2+ or ER+ metastatic breast cancer. JClin Oncol 2011, 29:e11024.
-
(2011)
JClin Oncol
, vol.29
-
-
Schroder, C.1
Pederson, J.V.2
Chua, S.3
Swanton, C.4
Akimov, M.5
Ide, S.6
-
27
-
-
49849088582
-
Aphase I trial of gemcitabine (Gem), 17-allylaminogeldanamcyin (17-AAG) and cisplatin (CDDP) in solid tumor patients
-
Abstract 3058
-
Haluska P., Toft D.O., Steinmetz S.M., Furth A., Mandrekar S., Stensgard B.A., et al. Aphase I trial of gemcitabine (Gem), 17-allylaminogeldanamcyin (17-AAG) and cisplatin (CDDP) in solid tumor patients. JClin Oncol 2004, 22. Abstract 3058.
-
(2004)
JClin Oncol
, vol.22
-
-
Haluska, P.1
Toft, D.O.2
Steinmetz, S.M.3
Furth, A.4
Mandrekar, S.5
Stensgard, B.A.6
-
28
-
-
84874428053
-
Aphase II trial of ganetespib: efficacy and safety in patients (pts) with metastatic breast cancer (MBC)
-
San Antonio, TX ; Abstract [P1-17-08]
-
Jhaveri K., Chandarlapaty S., Lake D., et al. Aphase II trial of ganetespib: efficacy and safety in patients (pts) with metastatic breast cancer (MBC). Proceedings of the 34th annual San Antonio breast cancer symposium 2011, San Antonio, TX ; Abstract [P1-17-08].
-
(2011)
Proceedings of the 34th annual San Antonio breast cancer symposium
-
-
Jhaveri, K.1
Chandarlapaty, S.2
Lake, D.3
-
29
-
-
84857060835
-
Phase 1 dose escalation study of the heat shock protein 90 inhibitor BIIB021 with trastuzumab in HER2 metastatic breast cancer
-
San Antonio, TX D 8-#2013;12
-
Modi S., Ismail-Khan R., Munster P., et al. Phase 1 dose escalation study of the heat shock protein 90 inhibitor BIIB021 with trastuzumab in HER2 metastatic breast cancer. Proceedings of the 33rd annual San Antonio breast cancer symposium 2010 Dec 8-12, San Antonio, TX.
-
(2010)
Proceedings of the 33rd annual San Antonio breast cancer symposium
-
-
Modi, S.1
Ismail-Khan, R.2
Munster, P.3
-
30
-
-
0031875042
-
The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin
-
Schulte T.W., Neckers L.M. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol 1998, 42:273-279.
-
(1998)
Cancer Chemother Pharmacol
, vol.42
, pp. 273-279
-
-
Schulte, T.W.1
Neckers, L.M.2
-
31
-
-
0142188139
-
Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors
-
Beliakoff J., Bagatell R., Paine-Murrieta G., Taylor C.W., Lykkesfeldt A.E., Whitesell L. Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors. Clin Cancer Res 2003, 9:4961-4971.
-
(2003)
Clin Cancer Res
, vol.9
, pp. 4961-4971
-
-
Beliakoff, J.1
Bagatell, R.2
Paine-Murrieta, G.3
Taylor, C.W.4
Lykkesfeldt, A.E.5
Whitesell, L.6
-
32
-
-
54349098717
-
Acombination of Trastuzumab and 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells
-
Raja S.M., Clubb R.J., Bhattacharyya M., Dimri M., Cheng H., Pan W., et al. Acombination of Trastuzumab and 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells. Cancer Biol Ther 2008, 7:1630-1640.
-
(2008)
Cancer Biol Ther
, vol.7
, pp. 1630-1640
-
-
Raja, S.M.1
Clubb, R.J.2
Bhattacharyya, M.3
Dimri, M.4
Cheng, H.5
Pan, W.6
-
33
-
-
0347993069
-
Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress
-
Arlander S.J., Eapen A.K., Vroman B.T., McDonald R.J., Toft D.O., Karnitz L.M. Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress. JBiol Chem 2003, 278:52572-52577.
-
(2003)
JBiol Chem
, vol.278
, pp. 52572-52577
-
-
Arlander, S.J.1
Eapen, A.K.2
Vroman, B.T.3
McDonald, R.J.4
Toft, D.O.5
Karnitz, L.M.6
-
34
-
-
17144377827
-
The role of checkpoint kinase 1 in sensitivity to topoisomerase I poisons
-
Flatten K., Dai N.T., Vroman B.T., Loegering D., Erlichman C., Karnitz L.M., et al. The role of checkpoint kinase 1 in sensitivity to topoisomerase I poisons. JBiol Chem 2005, 280:14349-14355.
-
(2005)
JBiol Chem
, vol.280
, pp. 14349-14355
-
-
Flatten, K.1
Dai, N.T.2
Vroman, B.T.3
Loegering, D.4
Erlichman, C.5
Karnitz, L.M.6
-
35
-
-
0034890377
-
Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters
-
Münster P.N., Basso A., Solit D., Norton L., Rosen N. Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters. Clin Cancer Res 2001, 7:2228-2236.
-
(2001)
Clin Cancer Res
, vol.7
, pp. 2228-2236
-
-
Münster, P.N.1
Basso, A.2
Solit, D.3
Norton, L.4
Rosen, N.5
-
36
-
-
0038404927
-
Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol
-
Solit D.B., Basso A.D., Olshen A.B., Scher H.I., Rosen N. Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer Res 2003, 63:2139-2144.
-
(2003)
Cancer Res
, vol.63
, pp. 2139-2144
-
-
Solit, D.B.1
Basso, A.D.2
Olshen, A.B.3
Scher, H.I.4
Rosen, N.5
-
37
-
-
0033890818
-
Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents
-
Bagatell R., Paine-Murrieta G.D., Taylor C.W., Pulcini E.J., Akinaga S., Benjamin I.J., et al. Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents. Clin Cancer Res 2000, 6:3312-3318.
-
(2000)
Clin Cancer Res
, vol.6
, pp. 3312-3318
-
-
Bagatell, R.1
Paine-Murrieta, G.D.2
Taylor, C.W.3
Pulcini, E.J.4
Akinaga, S.5
Benjamin, I.J.6
-
38
-
-
55749084036
-
Cisplatin abrogates the geldanamycin-induced heat shock response
-
McCollum A.K., Lukasiewicz K.B., Teneyck C.J., Lingle W.L., Toft D.O., Erlichman C. Cisplatin abrogates the geldanamycin-induced heat shock response. Mol Cancer Ther 2008, 7:3256-3264.
-
(2008)
Mol Cancer Ther
, vol.7
, pp. 3256-3264
-
-
McCollum, A.K.1
Lukasiewicz, K.B.2
Teneyck, C.J.3
Lingle, W.L.4
Toft, D.O.5
Erlichman, C.6
-
39
-
-
70350786146
-
Preparation of nanoparticle albumin bound 17AAG (nab-17AAG) suitable for intravenous administration
-
Abstract #1435
-
Tao C., Yu C., De T.K., Everett N., Frankel T., Ci S., et al. Preparation of nanoparticle albumin bound 17AAG (nab-17AAG) suitable for intravenous administration. Proc Amer Assoc Cancer Res 2005, 46. Abstract #1435.
-
(2005)
Proc Amer Assoc Cancer Res
, vol.46
-
-
Tao, C.1
Yu, C.2
De, T.K.3
Everett, N.4
Frankel, T.5
Ci, S.6
-
40
-
-
21244462689
-
Invivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative
-
Hollingshead M., Alley M., Burger A.M., Borgel S., Pacula-Cox C., Fiebig H.H., et al. Invivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative. Cancer Chemother Pharmacol 2005, 56:115-125.
-
(2005)
Cancer Chemother Pharmacol
, vol.56
, pp. 115-125
-
-
Hollingshead, M.1
Alley, M.2
Burger, A.M.3
Borgel, S.4
Pacula-Cox, C.5
Fiebig, H.H.6
-
41
-
-
21244466289
-
Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) invitro: effects on Hsp90 and client proteins in melanoma models
-
Smith V., Sausville E.A., Camalier R.F., Fiebig H.H., Burger A.M. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) invitro: effects on Hsp90 and client proteins in melanoma models. Cancer Chemother Pharmacol 2005, 56:126-137.
-
(2005)
Cancer Chemother Pharmacol
, vol.56
, pp. 126-137
-
-
Smith, V.1
Sausville, E.A.2
Camalier, R.F.3
Fiebig, H.H.4
Burger, A.M.5
-
42
-
-
33751258297
-
Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90
-
Sydor J.R., Normant E., Pien C.S., Porter J.R., Ge J., Grenier L., et al. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc Natl Acad Sci U S A 2006, 103:17408-17413.
-
(2006)
Proc Natl Acad Sci U S A
, vol.103
, pp. 17408-17413
-
-
Sydor, J.R.1
Normant, E.2
Pien, C.S.3
Porter, J.R.4
Ge, J.5
Grenier, L.6
-
43
-
-
79956001501
-
Antitumor activity of the Hsp90 inhibitor IPI-504 in HER2-positive trastuzumab-resistant breast cancer
-
Scaltriti M., Serra V., Normant E., Guzman M., Rodriguez O., Lim A.R., et al. Antitumor activity of the Hsp90 inhibitor IPI-504 in HER2-positive trastuzumab-resistant breast cancer. Mol Cancer Ther 2011, 10:817-824.
-
(2011)
Mol Cancer Ther
, vol.10
, pp. 817-824
-
-
Scaltriti, M.1
Serra, V.2
Normant, E.3
Guzman, M.4
Rodriguez, O.5
Lim, A.R.6
-
44
-
-
68849084042
-
Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib
-
Leow C.C., Chesebrough J., Coffman K.T., Fazenbaker C.A., Gooya J., Weng D., et al. Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib. Mol Cancer Ther 2009, 8:2131-2141.
-
(2009)
Mol Cancer Ther
, vol.8
, pp. 2131-2141
-
-
Leow, C.C.1
Chesebrough, J.2
Coffman, K.T.3
Fazenbaker, C.A.4
Gooya, J.5
Weng, D.6
-
45
-
-
73149118593
-
Phase 1/2 trial of the novel Hsp90 inhibitor, IPI-504, in patients with relapsed and/or refractory stage IIIb or stage IV non-small cell lung cancer (NSCLC) stratified by EGFR mutation status
-
Abstract B79
-
Sequist L., Janne P., Sweeney J., Walker J., Grayzel D., Lynch T. Phase 1/2 trial of the novel Hsp90 inhibitor, IPI-504, in patients with relapsed and/or refractory stage IIIb or stage IV non-small cell lung cancer (NSCLC) stratified by EGFR mutation status. AACR-NCI-EORTC International conference on molecular targets and cancer therapeutics 2007, Abstract B79.
-
(2007)
AACR-NCI-EORTC International conference on molecular targets and cancer therapeutics
-
-
Sequist, L.1
Janne, P.2
Sweeney, J.3
Walker, J.4
Grayzel, D.5
Lynch, T.6
-
46
-
-
51449118446
-
Inhibition of heat shock protein 90 (Hsp90) with the novel agent IPI-504 in metastatic GIST following failure of tyrosine kinase inhibitors (TKIs) or other sarcomas: clinical results from phase I trial
-
Abstract 10503
-
Wagner A.J., Morgan J.A., Chugh R., Rosen L.S., George S., Gordon M.S., et al. Inhibition of heat shock protein 90 (Hsp90) with the novel agent IPI-504 in metastatic GIST following failure of tyrosine kinase inhibitors (TKIs) or other sarcomas: clinical results from phase I trial. JClin Oncol 2008, 26(15 Suppl.). Abstract 10503.
-
(2008)
JClin Oncol
, vol.26
, Issue.15 SUPPL.
-
-
Wagner, A.J.1
Morgan, J.A.2
Chugh, R.3
Rosen, L.S.4
George, S.5
Gordon, M.S.6
-
47
-
-
84857042166
-
Aphase I doseescalation study of the Hsp90 inhibitor ganetespib (STA-9090) administered twice weekly in patients with solid tumors: updated report
-
Abstract 3051
-
Cho D., Heath E.I., Cleary J.M., Kwak E.L., Gandhi L., Lawrence D.P., et al. Aphase I doseescalation study of the Hsp90 inhibitor ganetespib (STA-9090) administered twice weekly in patients with solid tumors: updated report. JClin Oncol 2011, 29. Abstract 3051.
-
(2011)
JClin Oncol
, vol.29
-
-
Cho, D.1
Heath, E.I.2
Cleary, J.M.3
Kwak, E.L.4
Gandhi, L.5
Lawrence, D.P.6
-
48
-
-
79961009295
-
Aphase I dose-escalation study of the Hsp90 inhibitor STA-9090 administered once weekly in patients with solid tumors
-
Abstract 2529
-
Goldman J.W., Raju R.N., Gordon G.A., Vukovic V.M., Bradley R., Rosen L.S. Aphase I dose-escalation study of the Hsp90 inhibitor STA-9090 administered once weekly in patients with solid tumors. JClin Oncol 2010, 28(Suppl.). Abstract 2529.
-
(2010)
JClin Oncol
, vol.28
, Issue.SUPPL.
-
-
Goldman, J.W.1
Raju, R.N.2
Gordon, G.A.3
Vukovic, V.M.4
Bradley, R.5
Rosen, L.S.6
-
49
-
-
80455162319
-
Aphase 1 study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor in patients with refractory solid tumor malignancies and lymphomas
-
Rajan A., Kelly R.J., Trepel J.B., Kim Y.S., Alarcon S.V., Kummar S., et al. Aphase 1 study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor in patients with refractory solid tumor malignancies and lymphomas. Clin Cancer Res 2011, 17:6831-6839.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 6831-6839
-
-
Rajan, A.1
Kelly, R.J.2
Trepel, J.B.3
Kim, Y.S.4
Alarcon, S.V.5
Kummar, S.6
-
50
-
-
55249118494
-
BIIB021, an oral, synthetic non-ansamycin Hsp90 inhibitor: phase I experience
-
Abstract 2503
-
Elfiky A., Saif M.W., Beeram M., Brien O'., Lammanna N., Castron J.E., et al. BIIB021, an oral, synthetic non-ansamycin Hsp90 inhibitor: phase I experience. JClin Oncol 2008, 26. Abstract 2503.
-
(2008)
JClin Oncol
, vol.26
-
-
Elfiky, A.1
Saif, M.W.2
Beeram, M.3
Brien, O.'.4
Lammanna, N.5
Castron, J.E.6
-
51
-
-
42349084306
-
NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis
-
Eccles S.A., Massey A., Raynaud F.I., Sharp S.Y., Box G., Valenti M., et al. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res 2008, 68:2850-2860.
-
(2008)
Cancer Res
, vol.68
, pp. 2850-2860
-
-
Eccles, S.A.1
Massey, A.2
Raynaud, F.I.3
Sharp, S.Y.4
Box, G.5
Valenti, M.6
-
52
-
-
48949119477
-
NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models
-
Jensen M.R., Schoepfer J., Radimerski T., Massey A., Guy C.T., Brueggen J., et al. NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models. Breast Cancer Res 2008, 10:R33.
-
(2008)
Breast Cancer Res
, vol.10
-
-
Jensen, M.R.1
Schoepfer, J.2
Radimerski, T.3
Massey, A.4
Guy, C.T.5
Brueggen, J.6
-
53
-
-
79960983822
-
AUY922, a novel HSP90 inhibitor: final results of a first-in-human study in patients with advanced solid malignancies
-
Abstract 2528
-
Samuel T., Sessa C., Britten C., Milligan K.S., Mita M.M., Banerji U., et al. AUY922, a novel HSP90 inhibitor: final results of a first-in-human study in patients with advanced solid malignancies. JClin Oncol 2010, 28. Abstract 2528.
-
(2010)
JClin Oncol
, vol.28
-
-
Samuel, T.1
Sessa, C.2
Britten, C.3
Milligan, K.S.4
Mita, M.M.5
Banerji, U.6
-
55
-
-
84865794941
-
Molecular pathways: targeting hsp90-who benefits and who does not
-
Scaltriti M., Dawood S., Cortes J. Molecular pathways: targeting hsp90-who benefits and who does not. Clin Cancer Res 2012, 18:4508-4513.
-
(2012)
Clin Cancer Res
, vol.18
, pp. 4508-4513
-
-
Scaltriti, M.1
Dawood, S.2
Cortes, J.3
|